Two conditions, one patient: why prescribing patterns matter
Cardiovascular disease is a frequent companion to neurodegenerative illness. Many people living with Alzheimer's disease (AD) or Parkinson's disease (PD) are also managing heart conditions, which means oral anticoagulants and other cardiovascular medicines are a routine part of their treatment. Yet until recently, remarkably little was known about how those prescriptions evolve as a neurodegenerative disorder progresses. That gap matters: understanding real-world drug use in these populations is central to delivering safe, effective treatment, supporting clinicians at the point of care, and improving overall outcomes for patients.
New doctoral research from the University of Eastern Finland takes a direct look at the question. The work, conducted by Barkat Babar, examined how prevalent oral anticoagulant and cardiovascular drug use was among people with AD and PD in Finland, following prescriptions across an entire decade — five years before diagnosis and five years after.
Drawing on a decade of nationwide prescription records
The study leans on large Finnish healthcare registers, which capture medication use across the whole country rather than only within a single hospital or clinic. Combined with long follow-up windows, this design allowed the researchers to observe patterns among tens of thousands of people, moving from the years preceding a diagnosis into the years that follow it.
That long view is significant. A short study might pick up only a snapshot of prescribing at one moment, but neurodegenerative disorders unfold slowly, and treatment priorities often shift as symptoms accumulate. By bracketing the diagnosis with five years on either side, the research offers a timeline rather than a single point in time.
Oral anticoagulants in Alzheimer's disease: a rise, then a retreat
Among people with Alzheimer's disease, the use of oral anticoagulants climbed in the period before diagnosis, then fell away afterward. The researchers suggest this decline may stem from growing concern about safety as the disease advances — particularly the risk of falls and other adverse events, which become more likely as mobility, balance, and cognition deteriorate.
Anticoagulation is a balancing act under the best of circumstances. These drugs reduce the danger of clots and stroke, but they also raise the risk of bleeding, and a fall in a frail patient can turn a manageable risk into a serious one. The observed drop in use after an Alzheimer's diagnosis appears consistent with clinicians recalibrating that balance as patients become more vulnerable.
Parkinson's disease: anticoagulants hold steady
People with Parkinson's disease showed a different pattern. Their use of oral anticoagulants stayed relatively stable after diagnosis, which the research interprets as a sign that healthcare professionals judged the benefits of anticoagulant therapy to outweigh its potential harms in this group.
The contrast between the two conditions is one of the more striking findings. Two progressive neurological illnesses, two distinct trajectories for the same class of medication — a reminder that clinical judgment is being applied case by case rather than according to a single blanket rule.
Cardiovascular medicines taper off after a Parkinson's diagnosis
The picture changes again when the focus moves from anticoagulants to cardiovascular drugs as a broader category. Among people with Parkinson's disease, use of these medicines declined following diagnosis.
The research points to features of disease progression as a plausible explanation. Orthostatic hypotension — the drop in blood pressure that occurs when standing up — is a well-recognized complication of Parkinson's, and blood-pressure-lowering medications can make it worse. Weight loss, another common development as the disease progresses, may also influence how cardiovascular treatments are dosed or whether they are continued at all. In other words, the decline in prescribing may reflect the body's changing response to these drugs rather than a decision to deprioritize heart health.
Testing whether furosemide protects against Parkinson's disease
The dissertation also probed a separate and more speculative question: whether furosemide, a widely used diuretic, might lower the risk of developing Parkinson's disease. Earlier studies had hinted at a possible protective effect, giving the hypothesis enough weight to warrant a closer look in a large national dataset.
The results did not bear out a broad protective signal. No overall association emerged between furosemide use and Parkinson's disease risk. There was, however, a weak inverse relationship at the highest levels of exposure to the drug — meaning the heaviest users appeared slightly less likely to develop the condition. The researchers are careful to flag that this finding is preliminary and calls for further investigation before any conclusions are drawn.
Strengths of the evidence and where caution is warranted
A major strength of this work is its foundation in comprehensive Finnish health registers covering long periods. Real-world prescribing data of this scale and duration is difficult to assemble in any other way, and it captures what actually happens to patients rather than what happens under the tightly controlled conditions of a clinical trial.
That same design, however, comes with inherent limits. Register-based research documents patterns of medication use; it does not establish that one thing causes another. The observed shifts in prescribing could reflect a range of influences — clinical guidelines, individual patient circumstances, or the emergence of new symptoms — and the furosemide signal in particular remains a hypothesis in need of confirmation.
What the findings mean for care
Taken together, the results offer clinicians a clearer map of how medication use tends to move as Alzheimer's and Parkinson's progress. Key takeaways include:
- Oral anticoagulant use among people with Alzheimer's disease tends to rise before diagnosis and fall afterward, possibly reflecting heightened concern about falls and bleeding.
- Anticoagulant use among people with Parkinson's disease stays comparatively stable after diagnosis, suggesting that clinicians see the benefits as outweighing the risks.
- Cardiovascular drug use drops after a Parkinson's diagnosis, which may relate to progression symptoms such as orthostatic hypotension and weight loss.
- Furosemide showed no overall link to Parkinson's disease risk, with only a weak inverse association at the highest exposure levels — a result requiring more research.
For patients and families, the broader message is that medication plans in neurodegenerative disease are not static. As symptoms change, so too may the calculus behind each prescription. The Finnish data suggest that clinicians are already adapting treatment in response to disease progression — and that ongoing review of heart-related medications remains an essential part of long-term care for people living with Alzheimer's and Parkinson's disease.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
